Page 4 - Nasdaq Immx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201100% (8/8) overall response rate and 63% (5/8)...

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Rating) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totalling 221,300 shares, a growth of 86.8% from the April 15th total of 118,500 shares. Based on an average daily trading volume, of 201,700 shares, the days-to-cover ratio […]

Multiple Myeloma 92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic...

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Rating) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 146,500 shares, an increase of 24.3% from the February 28th total of 117,900 shares. Approximately 2.5% of the shares of the stock are short sold. Based on […]

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Rating) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 146,500 shares, a growth of 24.3% from the February 28th total of 117,900 shares. Based on an average daily volume of 182,200 shares, the days-to-cover ratio is […]